Broad Institute spin-out is pursuing drugs for intractable disease targets.
Ligon Discovery, which uses small molecule microarray technology to find drugs against high-value targets, has raised $1 million in seed financing led by incTANK Ventures. The company will use the capital to complete its initial discovery campaign that will screen over 100 high-value disease protein targets.
Patrick Kleyn, Ph.D., Angela Koehler, Ph.D., and Benjamin Ebert, M.D., Ph.D., founded Ligon Discovery with an exclusive license to technology invented at Harvard University. According to Dr. Kleyn, “Ligon’s technology has already been used to discover drug compounds against high-value targets including protein kinases, histone deacetylases, extracellular growth factors, and transcription factors.”
Ligon Discovery’s high-throughput microarray “chip” reportedly transforms the speed of the drug discovery process and expands the scope of new drug prospecting to include previously intractable targets.